Cutaneous malignant melanoma and Parkinson disease: Common pathways?

Area of Science:

• Neuroscience
• Oncology
• Genetics

Background:

• Parkinson disease (PD) and cutaneous malignant melanoma (CMM) exhibit a high comorbidity.
• The molecular mechanisms linking PD and CMM remain largely unknown.
• 129Ser-phosphorylated alpha-synuclein, a key pathological marker in PD, is notably present in CMM but absent in healthy skin.

Purpose of the Study:

• To explore the potential shared genetic pathways and molecular intersections between Parkinson disease and cutaneous malignant melanoma.
• To review genetic links, including PARK genes and melanogenesis-related genes, that may contribute to the comorbidity of PD and CMM.

Main Methods:

• Literature review of genetic associations between Parkinson disease and cutaneous malignant melanoma.
• Analysis of shared cellular origins (neural crest) and functional capabilities (melanogenesis).
• Examination of gene mutations (germline in PD, somatic in CMM) and protein involvement in both conditions.

Main Results:

• Parkinson disease-associated genes (PARK genes) are implicated in both inherited PD and somatic mutations in CMM.
• Alpha-synuclein, a hallmark of PD pathology, is expressed in CMM.
• Genes associated with CMM risk also influence PD risk, indicating a potential genetic overlap.
• Shared neural crest cell origin and melanogenesis capability in PD and CMM cells.

Conclusions:

• Genetic intersections and shared pathways likely contribute to the high prevalence of CMM in Parkinson disease patients.
• Further research into these shared pathways may reveal novel therapeutic targets for both neurodegenerative and oncological conditions.
• Pigmentation gene variants may play a role in the susceptibility to both PD and CMM.